deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02266628

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

A Phase II Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine in Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients

Sponsor: Novavax

Conditions Respiratory Syncytial Virus (RSV)
Interventions RSV-F Vaccine Saline Placebo
Updated 9 times since 2017 Last updated: May 25, 2022 Started: Oct 31, 2014 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02266628, this PHASE2 trial focuses on Respiratory Syncytial Virus (RSV) and remains completed. Sponsored by Novavax, it has been updated 9 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotCompleted~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshotCompleted~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Jun 2022 [monthly]

    Completed PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jul 2017 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novavax
Data source: Novavax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations